In the review article by Wood l under 'other influencing factors' the following statement is given: 'Evidence suggests that intact PTH concentrations in ambulatory geriatric patients are no different from those in normal adults' .... I would like to point out that a large number of studies show that serum PTH concentration increases with age. 2 -13 The assays used in these studies include assays for the intact molecule, or the N terminal>? mid molecule-" or the C terminal section of the molecule.v" Furthermore, in at least one study the immunoassay was validated by comparison with biological activity measured using renal adenyl cyclase assay system. Urinary cyclic AMP excretion, an index of PTH activity also increases with age. 3 -7 Recently in a study of 157 female subjects we showed that serum intact PTH concentration measured by a cherniluminometricassay (Magiclite) increased with age (r=0'591, P<0·OOI).14 This effect of age on PTH concentration was significant even after taking into account the decline in glomerular filtration rate (partial correlation coefficient=0'407, P<O·OOI). significant increase in intact PTH concentration was not found in post-menopausal women. Younger women (less than 40 years of age) were not included in this study and this may be the reason for the lack of effect.
It is also quoted in this review article that '20 of 39 elderly patients with hip fractures were found to have elevated intact PTH results' .16 However, the reviewer failed to point out that in this study a control group of elderly subjects were not included. Cooper et al. 17 showed that there was no difference in serum PTH concentration between elderly patients with hip fracture and control subjects. In a study of 61 female patients with hip fractures and 61 age matched control subjects we could not show any difference in serum PTH measured by a chemiluminometric assay (Macdonald et al., unpublished observations Author's reply
The PTH review emphasized the fact that earlier, competitive RIAs for PTH were of dubious specificity, and that for this reason publications which did not utilize the new twosite assays for intact PTH had been discounted. The great majority of references cited by Professor Swaminathan fall into this category. In the past it has been extremely difficult to discriminate between the effects of diminishing renal function and possible increases in PTH secretion as a cause of increased serum PTH RIA results with age. At the time of submission of the review (April 1991) there were few reports of serum intact PTH changes with age, despite a thorough computer literature search, but I accept that now there is evidence of a small but significant increase. The situation with hip fracture is a similar one. I could find only one published study using intact PTH measurements, and even our own report I must be discounted as it utilized a C-terminalspecificity antiserum which may not distinguish subtle differences between serum intact PTH concentrations in patients and controls.
Professor Swaminathan's new data will be an interesting and valuable addition to the literature and I look forward to seeing his results when they are published. 1989; 5: 193-200 Antibody interference in free thyroxine assays
Beckett in his evaluation of the Delfia twostep, non-isotopic assay for free thyroxine (FT4) highlights two patients in whom the serum FT4 concentrations were inappropriately high. I In one patient, who was hypothyroid, an elevated FT 4 of 28 pmoliL was found which apparently increased to 48 pmollL when reassayed by a modified procedure intended to eliminate interference due to antibodies. In a second patient a FT 4 concentration of > 56 pmol/L was reduced to 17 pmollL using this procedure suggesting the presenceof interferingantibodiesin the patient's serum. In a limited evaluation of the Delfia two-step assay for FT4 we also discovered one patient who gave an erroneously high Ff4 concentration of 82 pmollL. After the addition to the sample of polyethylene glycol and centrifugation, to eliminate antibody interference, the supernatant was reassayed and the measured FT4 was 95 pmollL. The Ff 4 concentration by a one-step analogue method, Amerlex-M (Amersham International), was found to be II pmollL with a normal TSH concentration by an in-house assay suggesting the patient was euthyroid. Clearly the erroneously high Ff4 estimate in the Delfia assay was not due to an antibody interference and we were unable to identify the cause of the spuriously increased Ff 4 concentration.
Antibody interference is a relatively uncommon occurrence in analogue one-step Ff 4 methods. In samples received for thyroid function testing an incidence of antibody interference of one in 2460 has been observed." The majority of samples had thyroid autoantibodies present which were thought to be responsible for the binding of radio-labelled T4 analogue causing the spuriously increased FT 4 concentrations. In two-step FT 4 methods this antibody interference is avoided, as a washing step ensures that serum does not come into contact with radiolabelled T 4 or T 4 analogue. However, the design of some two-step Ff4 assays does allow heterophilic antibody present in the patient's serum to be a cause of spuriously increased FT 4 concentration in some instances.
All users of the Delfia FT4 assay. should be aware that problems can arise with certain samples and any discrepant Ff4 concentration should be checked by another assay procedure.
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